Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC)
NCT ID: NCT00286169
Last Updated: 2022-04-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
130 participants
INTERVENTIONAL
2006-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer
NCT00660504
Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.
NCT00319969
Amrubicin (AMR) Trial in Patients With Non-small Cell Lung Cancer
NCT01207011
Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer
NCT00388960
Amrubicin and Irinotecan in Treating Patients With Recurrent or Relapsed Extensive Stage Small Cell Lung Cancer
NCT00132054
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Amrubicin Hydrochloride
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged 70 years or older
* Performance status of 0-2
* No prior chemotherapy
Exclusion Criteria
* Pneumonitis and/or pulmonary fibrosis
* Active concomitant malignancy
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sumitomo Pharma Co., Ltd.
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Drug Development Division
Role: STUDY_DIRECTOR
Sumitomo Pharma Co., Ltd.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chugoku Region Site
Chugoku, , Japan
Chubu Region Site
Chūbu, , Japan
Hokkaido Region Site
Hokkaido, , Japan
Kanto Region Site
Kanto, , Japan
Kinki Region Site
Kinki, , Japan
Kyushu Region Site
Kyushu, , Japan
Shikoku Region Site
Shikoku, , Japan
Tohoku Region Site
Tōhoku, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JapicCTI-060203
Identifier Type: -
Identifier Source: secondary_id
D0702002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.